CliffBio
small molecule

INVEGA TRINZA

PALIPERIDONE PALMITATE

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyJanssen Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameINVEGA TRINZA
Active ingredientPALIPERIDONE PALMITATE
Strength273MG/0.875ML (273MG/0.875ML)
Dosage formSUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalMay 2015
Marketing statusRX

Listed patents

PatentExpiresType
10143693April 2036use U-2457

More from Janssen Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INVEGA TRINZA patent cliff — loss of exclusivity April 2036 | CliffBio